“Mor Yong” reveals information about the covid vaccine, protein subunit type, protein-producing organisms Helping to boost immunity against COVID-19
Today (8 May 65) Prof. Dr. Yong Phu Worawan, the head of the center specializes in virology. Clinic, Department of Pediatrics Faculty of Medicine Chulalongkorn University Post a message on his personal Facebook page “Yong Poovorawan” on the topic of COVID-19 vaccine, protein subunit, stating:
“Now Thailand There is a type 4 vaccine available to the Thai population. It is a protein subunit, Covovax vaccine from India. It is a licensed vaccine and method like Novavax vaccine in the United States. subunit protein The use of vaccines for COVID is not a new principle. This vaccine is already in use, for example the hepatitis B vaccine is used a lot.
But covid-19 protein sprites will be large, stimulating immunity. Therefore, special techniques are required. To be an additional aid is to use an adjuvant or a booster to boost immunity. come as a component
The protein subunit Chinese vaccine ZF2001, trade name Zifivax, was developed by Anhui Zhifei Longcom. The injection therefore requires up to 3 needles and the landscape is not very high.
The vaccines to speak of are Novavax and Covovax which are available in Thailand. use the same principle Let living things make proteins. like that of the covid virus protein sprite.
The focus of this vaccine is an adjuvant. The Matrix M adjuvant is used as a saponin derived from the bark of the Molina tree. It is new and has recently been used in this vaccine. It has not been used in humans before. Therefore, it has been studied from Phase I to Phase 3 and has been used. Its use as a stimulant is not yet known. It can be seen that this vaccine has passed Phase 3 for a year and a half. has just been put into practice.
another vaccine To be mentioned is the tobacco leaf vaccine. protein made from tobacco leaves The vaccine is Medicago, Canada. The vaccine, trade name Covifenz, is based on GSK’s ASO3 inhibitor. in cervical cancer vaccine stimulate high immunity and have confidence in the matter of safety and successfully passed the 3rd phase of the experiment It is about 70 percent effective in preventing disease, reducing moderate and severe disease severity by 78.8 percent.”
Barriers to protein-based vaccines It’s not about making proteins from living things. The big problem lies in enhancing substances. Stimulate immunity (adjuvant) that is used. good performance Will be licensed, such as Matrix M, ASO3. Matrix M is a new thing, just started to be used in humans. There has to be a follow-up on safety as well.”
Image from AFP/MOPH.